{"name": "Myriad Pharmaceuticals",
 "permalink": "myriad-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/myriad-pharmaceuticals",
 "homepage_url": "http://www.myriadpharma.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "801-214-7822",
 "description": "",
 "created_at": "Sat Dec 19 07:49:33 UTC 2009",
 "updated_at": "Sat Apr 17 18:18:35 UTC 2010",
 "overview": "\u003Cp\u003EMyriad Pharmaceuticals, Inc. is focused on discovering, developing, and commercializing novel small molecule drugs for the treatment of diseases with high unmet need, including cancer and HIV infection. Our pipeline includes clinical and pre-clinical product candidates with distinct mechanisms of action and novel chemical structures that have the potential to be first-in-class and/or best-in-class therapeutics.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       39],
      "assets/images/resized/0007/0418/70418v1-max-150x150.png"],
     [[250,
       66],
      "assets/images/resized/0007/0418/70418v1-max-250x250.png"],
     [[297,
       79],
      "assets/images/resized/0007/0418/70418v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President \u0026 CEO",
    "person":
     {"first_name": "Adrian",
      "last_name": "N. Hobden",
      "permalink": "adrian-n-hobden",
      "image": null}},
   {"is_past": false,
    "title": "COO",
    "person":
     {"first_name": "Wayne",
      "last_name": "Laslie",
      "permalink": "wayne-laslie",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [{"price_amount": 95000000.0,
    "price_currency_code": "USD",
    "term_code": "stock",
    "source_url": "http://www.masshightech.com/stories/2009/12/14/daily69-Javelin-Pharma-acquired-by-Myriad-for-91M.html",
    "source_description": "Javelin Pharma acquired by Myriad for at least $95M",
    "acquired_year": 2009,
    "acquired_month": 12,
    "acquired_day": 18,
    "company":
     {"name": "Javelin Pharmaceuticals",
      "permalink": "javelin-pharmaceuticals",
      "image":
       {"available_sizes":
         [[[150,
            49],
           "assets/images/resized/0007/0416/70416v1-max-150x150.png"],
          [[250,
            83],
           "assets/images/resized/0007/0416/70416v1-max-250x250.png"],
          [[250,
            83],
           "assets/images/resized/0007/0416/70416v1-max-450x450.png"]],
        "attribution": null}}}],
 "offices":
  [{"description": "",
    "address1": "320 Wakara Way ",
    "address2": "",
    "zip_code": "84108",
    "city": "Salt Lake City",
    "state_code": "UT",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Javelin terminates merger agreement with Myriad.",
    "stoned_year": 2010,
    "stoned_month": 4,
    "stoned_day": 17,
    "source_url": "http://www.fiercebiotech.com/story/javelin-jilts-myriad-favor-hospiras-141m-takeover-offer/2010-04-12",
    "source_text": "Javelin Pharmaceuticals is dumping Myriad Pharmaceuticals and its $81 million takeover deal in exchange for a much, much better deal from Hospira. Javelin shares skyrocketed 63 percent this morning after it announced that Hospira will pay $141 million for the company.\r\n\r\nRead more: http://www.fiercebiotech.com/story/javelin-jilts-myriad-favor-hospiras-141m-takeover-offer/2010-04-12#ixzz0lNn2uETC",
    "source_description": "",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Myriad Pharmaceuticals",
      "permalink": "myriad-pharmaceuticals"}}],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "MYRX"},
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        82],
       "assets/images/resized/0007/0417/70417v1-max-150x150.jpg"],
      [[250,
        137],
       "assets/images/resized/0007/0417/70417v1-max-250x250.jpg"],
      [[450,
        246],
       "assets/images/resized/0007/0417/70417v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}